Truvestments Capital’s Lipocine LPCN Stock Holding History

Truvestments Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-83	Closed	-$560	–	841
2022 Q4	$560	Hold	83	–	–	﹤0.01%	861
2022 Q3	$1K	Hold	83	–	–	﹤0.01%	593
2022 Q2	$1K	Buy	+83	New	+$1.29K	﹤0.01%	607

Other funds holding LPCN

EWA

EP Wealth Advisors Torrance, California $20.3B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Truvestments Capital's LPCN Position: Q1 2023 in Review

Truvestments Capital sold out of Lipocine (LPCN) in Q1 2023, closing a stake of 83 shares — an estimated $560 sold.

Truvestments Capital first reported a position in LPCN in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 45 funds tracked by Wall St. Rank hold LPCN as of Q1 2023.

Truvestments Capital reported no remaining Lipocine position as of Q1 2023 after selling out during the quarter.
Truvestments Capital sold 83 Lipocine shares in Q1 2023, an estimated $560.
Truvestments Capital first reported a position in Lipocine in Q2 2022 and held it in 3 quarters.
Truvestments Capital's Lipocine position peaked at $1K in Q3 2022.
45 funds tracked by Wall St. Rank held Lipocine as of Q1 2023.

Based on Truvestments Capital's 13F filing for Q1 2023, filed 12 May 2023.